Mycophenolate Mofetil As Second Line Treatment in Autoimmune Hepatitis - A Retrospective Single Center Analysis

Overview

Journal J Transl Autoimmun

Date 2022 Dec 1

PMID 36451933

Authors

Mirjam Kolev

Stefan Diem

Lara Diem

Susana G Rodrigues

Annalisa Berzigotti

Guido Stirnimann

Nasser Semmo

Affiliations

Soon will be listed here.

Abstract

Background: Most patients with autoimmune hepatitis respond to standard treatment with steroids and azathioprine. While the disease is usually fatal if untreated, patients who respond well to therapy have an excellent prognosis. Nevertheless, second-line treatment is necessary in approximately 20% of patients, due to either intolerance or insufficient response to first line treatment.While data for mycophenolate mofetil (MMF) in patients intolerant to azathioprine is encouraging, MMF seems of less benefit in patients with insufficient response to first line treatment, but analyzed data on this issue is limited.

Aim: To evaluate the efficacy and safety of MMF as a second-line therapy in patients with AIH.

Methods: Retrospective analysis of a monocentric database of AIH patients who received medical care from 2000 to 2022. Clinical, immunological and biochemical parameters were assessed at different time points including last follow-up.

Results: Overall, 144 patients with AIH were identified. Fifty out of 144 (35%) AIH patients received MMF. Forty (80%) received MMF due to first line treatment intolerance, while ten (20%) due to insufficient response to first line treatment.Remission with MMF monotherapy was 81.5% in the intolerance group versus 30% in the insufficient response group. Patients switched to MMF because of an insufficient response, more often needed additional prednisolone doses higher than 5 mg/day, a switch to third-line treatment or combination regiments, to achieve disease control.

Conclusions: Patients treated with MMF because of intolerance to first line treatment show a good disease control under MMF in the majority of cases. Efficacy is considerably lower in the patients switched to MMF because of an insufficient response to first line treatment.

Citing Articles

autoimmune hepatitis? - Summary of the 5 international autoimmune hepatitis group research workshop 2024.

Engel B, Assis D, Bhat M, Clusmann J, Drenth J, Gerussi A JHEP Rep. 2025; 7(2):101265.

PMID: 39897612 PMC: 11783120. DOI: 10.1016/j.jhepr.2024.101265.

Autoimmune hepatitis: Towards a personalized treatment.

Costaguta A, Costaguta G, Alvarez F World J Hepatol. 2024; 16(11):1225-1242.

PMID: 39606175 PMC: 11586748. DOI: 10.4254/wjh.v16.i11.1225.

Hellenic Association for the Study of the Liver (HASL): revised clinical practice guidelines for autoimmune hepatitis.

Dalekos G, Papatheodoridis G, Koskinas J, Goulis I, Rigopoulou E, Tiniakos D Ann Gastroenterol. 2024; 37(6):623-654.

PMID: 39568707 PMC: 11574148. DOI: 10.20524/aog.2024.0924.

References

Cook G, Mulligan R, Sherlock S . Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971; 40(158):159-85. DOI: 10.1093/oxfordjournals.qjmed.a067264. View

Sammaritano L, Bermas B, Chakravarty E, Chambers C, Clowse M, Lockshin M . 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2020; 72(4):461-488. DOI: 10.1002/acr.24130. View

Summerskill W, Korman M, Ammon H, BAGGENSTOSS A . Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975; 16(11):876-83. PMC: 1413126. DOI: 10.1136/gut.16.11.876. View

Allison A . Mechanisms of action of mycophenolate mofetil. Lupus. 2005; 14 Suppl 1:s2-8. DOI: 10.1191/0961203305lu2109oa. View

Hlivko J, Shiffman M, Stravitz R, Luketic V, Sanyal A, Fuchs M . A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008; 6(9):1036-40. DOI: 10.1016/j.cgh.2008.04.006. View

Chatur N, Ramji A, Bain V, Ma M, Marotta P, Ghent C . Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005; 25(4):723-7. DOI: 10.1111/j.1478-3231.2005.01107.x. View

Dalekos G, Arvaniti P, Gatselis N, Samakidou A, Gabeta S, Rigopoulou E . First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients. Front Immunol. 2022; 12:798602. PMC: 8787111. DOI: 10.3389/fimmu.2021.798602. View

Murray-Lyon I, Stern R, Williams R . Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973; 1(7806):735-7. DOI: 10.1016/s0140-6736(73)92125-9. View

Zolfino T, Heneghan M, Norris S, Harrison P, Portmann B, McFarlane I . Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut. 2002; 50(5):713-7. PMC: 1773189. DOI: 10.1136/gut.50.5.713. View

10.

Dalekos G, Arvaniti P, Gatselis N, Gabeta S, Samakidou A, Giannoulis G . Long-term results of mycophenolate mofetil . azathioprine use in individuals with autoimmune hepatitis. JHEP Rep. 2022; 4(12):100601. PMC: 9674541. DOI: 10.1016/j.jhepr.2022.100601. View

11.

Zachou K, Gatselis N, Papadamou G, Rigopoulou E, Dalekos G . Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol. 2011; 55(3):636-646. DOI: 10.1016/j.jhep.2010.12.032. View

12.

Pape S, Snijders R, Gevers T, Chazouilleres O, Dalekos G, Hirschfield G . Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol. 2022; 76(4):841-849. DOI: 10.1016/j.jhep.2021.12.041. View

13.

Sharzehi K, Huang M, Schreibman I, Brown K . Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010; 24(10):588-92. PMC: 2975470. DOI: 10.1155/2010/891252. View

14.

Wolf D, Bojito L, Facciuto M, Lebovics E . Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci. 2008; 54(11):2519-22. DOI: 10.1007/s10620-008-0632-0. View

15.

Seela S, Sheela H, Boyer J . Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int. 2005; 25(4):734-9. DOI: 10.1111/j.1478-3231.2005.01141.x. View

16.

Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J . A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl. 2001; 7(5):442-50. DOI: 10.1053/jlts.2001.23356. View

17.

Czaja A . Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree. J Hepatol. 2009; 51(1):8-10. DOI: 10.1016/j.jhep.2009.03.011. View

18.

Bedossa P, Poynard T . An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2):289-93. DOI: 10.1002/hep.510240201. View

19.

Jothimani D, Cramp M, Cross T . Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study. J Clin Exp Hepatol. 2015; 4(3):221-5. PMC: 4284212. DOI: 10.1016/j.jceh.2014.05.003. View

20.

van den Brand F, van der Veen K, Lissenberg-Witte B, de Boer Y, van Hoek B, Drenth J . Adverse events related to low dose corticosteroids in autoimmune hepatitis. Aliment Pharmacol Ther. 2019; 50(10):1120-1126. PMC: 6899908. DOI: 10.1111/apt.15528. View